| Generic name | Selinexor |
| Brand name(s), other common name(s) | Xpovio® |
| Drug type | SINE (Selective Inhibitor of Nuclear Export) Compound (this is a first-in-class SINE compound) |
| How the drug is given | Oral |
Indications and Usage
Selinexor is FDA approved
- In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
- In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody
- For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
These indications are approved under accelerated approval based on response rate. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.
Side effects needing medical attention
The most common adverse reactions in patients with multiple myeloma are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia (concentration of sodium in your blood is abnormally low), neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection.
The most common adverse reactions in patients with DLBCL, excluding laboratory abnormalities, are fatigue, nausea, diarrhea, appetite decrease, weight decrease, constipation, vomiting, and fever. Grade 3-4 laboratory abnormalities are thrombocytopenia, lymphopenia, neutropenia, anemia, and hyponatremia.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.